1. Home
  2. IREN vs MIRM Comparison

IREN vs MIRM Comparison

Compare IREN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iris Energy Limited

IREN

Iris Energy Limited

N/A

Current Price

$14.41

Market Cap

8.3B

Sector

Technology

ML Signal

N/A

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

N/A

Current Price

$95.51

Market Cap

7.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IREN
MIRM
Founded
2018
2018
Country
Australia
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
7.2B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
IREN
MIRM
Price
$14.41
$95.51
Analyst Decision
Buy
Strong Buy
Analyst Count
20
12
Target Price
$56.69
★ $157.71
AVG Volume (30 Days)
★ 54.9M
514.2K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 74.59
EPS
★ N/A
N/A
Revenue
★ $707,007,000.00
$19,138,000.00
Revenue This Year
$237.43
$37.65
Revenue Next Year
$199.66
$21.04
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 41.11
N/A
52 Week Low
$14.98
$63.23
52 Week High
$70.71
$130.00

Technical Indicators

Market Signals
Indicator
IREN
MIRM
Relative Strength Index (RSI) 26.73 60.65
Support Level N/A $87.38
Resistance Level $44.21 $98.34
Average True Range (ATR) 2.13 4.13
MACD -0.17 0.32
Stochastic Oscillator 2.29 75.22

Price Performance

Historical Comparison
IREN
MIRM

About IREN Iris Energy Limited

IREN owns data centers powered by renewable energy in Canada and the US for bitcoin mining and AI cloud infrastructure. The company is in the process of converting its existing bitcoin capacity for AI purposes and securing new power and land supply to expand its data center operations. IREN works closely with industry leaders in AI, such as Microsoft, to support their cloud infrastructure ambitions.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: